Ganz, P. A., Bandos, H., Španić, T., Friedman, S., Müller, V., Kuemmel, S., . . . Tutt, A. N. (2024). Patient-reported outcomes in OlympiA: A Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. Journal of clinical oncology, 42(11), . https://doi.org/10.1200/JCO.23.01214
Chicago-Zitierstil (17. Ausg.)Ganz, Patricia A., et al. "Patient-reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-controlled Trial of Adjuvant Olaparib in GBRCA1/2 Mutations and High-risk Human Epidermal Growth Factor Receptor 2-negative Early Breast Cancer." Journal of Clinical Oncology 42, no. 11 (2024). https://doi.org/10.1200/JCO.23.01214.
MLA-Zitierstil (9. Ausg.)Ganz, Patricia A., et al. "Patient-reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-controlled Trial of Adjuvant Olaparib in GBRCA1/2 Mutations and High-risk Human Epidermal Growth Factor Receptor 2-negative Early Breast Cancer." Journal of Clinical Oncology, vol. 42, no. 11, 2024, https://doi.org/10.1200/JCO.23.01214.